Southeast Asia is seeing a rise in the risk factors of heart failure which will inevitably increase the epidemic of heart failure. In a first-ever prospective, multinational real-world data examination of prescription patterns and doses attained of guideline-directed medical therapies in Asian patients suffering from heart failure with reduced ejection fraction (HFrEF), a team of researchers studied the prescription patterns and doses attained of guideline-directed medical therapies in Asian HFrEF patients, and the associations with patient outcomes. The research findings provided valuable insights into the importance of guideline recommendations to prescribe evidence-based therapies to achieve maximum benefits among Asian patients with HFrEF. They also highlighted the gaps in knowledge and treatment.
Click here for the full article (in Mandarin).
Subscribe to our mailing list to get the updates to your email inbox...